Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Temsirolimus and Lenalidomide in Relapsed Lymphomas
NCT01076543Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Apr 2010
- Primary completion
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of temsirolimus and lenalidomide in Hodgkin lymphoma (HL), non-Hodgkin lymphoma (NHL), follicular lymphoma (FL) and 6 more, sponsored by National Cancer Institute. Primary endpoints: Dose-limiting Toxicity at 28 days, Complete Response at 1 year and 1 more. Started Apr 2010; status: completed.
02
Drugs
temsirolimuslenalidomide
03
Conditions
Hodgkin lymphoma (HL)non-Hodgkin lymphoma (NHL)follicular lymphoma (FL)diffuse large B-cell lymphoma (DLBCL)Lymphoplasmacytic Lymphoma (LPL)
Beyond the preview
Go deeper on NCT01076543.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01076543.